Core Viewpoint - Shandong Lukang Pharmaceutical Co., Ltd. is enhancing its innovation capabilities and focusing on biomanufacturing to drive growth and transformation in the pharmaceutical industry [1][2][3] Group 1: Company Overview - Established in 1966, Lukang Pharmaceutical is a major biopharmaceutical enterprise in China, recognized as a key antibiotic research and production base [1] - The company is ranked 51st among Chinese pharmaceutical companies by the Ministry of Industry and Information Technology for 2024 [1] Group 2: Innovation and Product Development - The company has invested heavily in technological innovation, optimizing its product structure with multiple innovative drugs entering clinical trials during the 14th Five-Year Plan [1] - It has approved 35 new generic drugs and achieved consistency evaluation for 85 product specifications, enhancing competitiveness in anti-infection, diabetes, and cardiovascular drugs [1] - The company is transitioning from traditional microbial fermentation to synthetic biology applications, aiming to establish a globally influential biomanufacturing innovation hub [2][5] Group 3: Strategic Partnerships and Collaborations - Lukang Pharmaceutical is strengthening partnerships with renowned universities and research institutions to enhance research and development capabilities [4] - The company has signed strategic cooperation agreements with institutions like Shandong University and Wuhan University to accelerate the development of innovative drugs and high-end formulations [4] Group 4: Technological Advancements - The company is building a comprehensive innovation system that integrates basic research, technology transfer, and industrialization, focusing on synthetic biology technology as a new growth point [3] - It has established a biomanufacturing system characterized by a platform for technology transfer and multiple supporting directions, including the world's first green biomanufacturing project for trans-aconitic acid [5]